<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02498431</url>
  </required_header>
  <id_info>
    <org_study_id>IRICARDIO</org_study_id>
    <nct_id>NCT02498431</nct_id>
  </id_info>
  <brief_title>Serum Irisin in Myocardial Infraction and Following Percutaneous Coronary Intevention</brief_title>
  <acronym>IRICARDIO</acronym>
  <official_title>Serum Irisin Levels in Myocardial Infraction and Following Percutaneous Coronary Intevention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>424 General Military Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>424 General Military Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to evaluate circulating irisin levels alterations in patients with
      acute myocardial infraction and in patients with coronary artery disease subjected to
      percutaneous coronary intervention.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Irisin is a newly discovered myokine induced in exercise. There is evidence that cardiac
      muscle produces more irisin than skeletal muscle in response to exercise. Furthermore, irisin
      has been associated with isoproterenol-induced myocardial infarction (MI) in rats while it
      has been reported to decrease after acute myocardial infarction in humans.

      The investigators aim 1) to investigate circulating irisin levels in patients at the time of
      acute myocardial infarction and after reprefusion [primary percutaneous coronary intervention
      (PCI)] 2) to compare irisin' s diagnostic and prognostic value and specificity value in
      myocardial infarction with known markers of cardiac injury such as creatine kinase-MB
      isoenzyme (CK-MB) and troponin 3) to evaluate irisin as an early necrosis biomarker 4) To
      evaluate irisin's sensitivity as a biomarker to detect minor myocardial necrosis after
      elective percutaneous coronary intervention
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>changes from baseline in serum irisin measured by ELISA</measure>
    <time_frame>baseline and 6 hours or 24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes from baseline in troponin</measure>
    <time_frame>baseline and 6 hours or 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes from baseline in serum lactate dehydrogenase</measure>
    <time_frame>baseline and 6 hours or 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes from baseline in serum creatine kinase</measure>
    <time_frame>baseline and 6 hours or 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes from baseline in serum creatine kinase-MB isoenzyme</measure>
    <time_frame>baseline and 6 hours or 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes from baseline in serum follistatin</measure>
    <time_frame>baseline and 6 hours or 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes from baseline in serum follistatin-like protein 3 (FSTL-3)</measure>
    <time_frame>baseline and 6 hours or 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes from baseline in serum Activin A</measure>
    <time_frame>baseline and 6 hours or 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes from baseline in serum Activin B</measure>
    <time_frame>baseline and 6 hours or 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes from baseline in serum insulin growth factor 1 (IGF1)</measure>
    <time_frame>baseline and 6 hours or 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes from baseline in serum insulin growth factor binding protein 3 (IGFBP3)</measure>
    <time_frame>baseline and 6 hours or 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes from baseline in serum insulin growth factor binding protein 4 (IGFBP4)</measure>
    <time_frame>baseline and 6 hours or 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes from baseline in serum pico pregnancy-associated plasma protein A (PAPP-A)</measure>
    <time_frame>baseline and 6 hours or 24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>myocardial infraction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with acute myocardial infraction who are admitted to the emergency department of 424 General Military Hospital before and after percutaneous coronary intervention and stent placement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>coronary artery disease</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with coronary artery disease but not myocardial infraction who are being subjected to coronary angiography and percutaneous coronary intervention and stent placement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients subjected to coronary angiography and found with no presence of coronary artery disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>percutaneous coronary intervention</intervention_name>
    <description>a non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease</description>
    <arm_group_label>myocardial infraction</arm_group_label>
    <arm_group_label>coronary artery disease</arm_group_label>
    <other_name>coronary angioplasty</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>coronary angiography</intervention_name>
    <description>is a procedure performed along with cardiac catheterization that uses X-ray imaging to see your heart's blood vessels</description>
    <arm_group_label>myocardial infraction</arm_group_label>
    <arm_group_label>coronary artery disease</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Stent, Medronic Resolute Integrity</intervention_name>
    <description>A stent is placed in an artery as part of a procedure called percutaneous coronary intervention (PCI) to restore blood flow through narrow or blocked arteries. A stent helps support the inner wall of the artery in the months or years after PCI.</description>
    <arm_group_label>myocardial infraction</arm_group_label>
    <arm_group_label>coronary artery disease</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with acute myocardial infraction (MI) or with coronary artery disease without
             myocardial infraction who need percutaneous coronary intervention

        Exclusion Criteria:

          -  age &lt; 20 years old

          -  diseases or medications that could affect cardiac muscle or skeletal muscle metabolism

          -  musculoskeletal injury of surgery 6 months prior to recruitment

          -  severe liver or kidney disease (creatinine clearance &lt; 60ml/min/1.73m2) or liver or
             kidney transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Athanasios D Anastasilakis, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>424 General Military Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>424 General Military Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <zip>56429</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <reference>
    <citation>Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, Rasbach KA, Boström EA, Choi JH, Long JZ, Kajimura S, Zingaretti MC, Vind BF, Tu H, Cinti S, Højlund K, Gygi SP, Spiegelman BM. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012 Jan 11;481(7382):463-8. doi: 10.1038/nature10777.</citation>
    <PMID>22237023</PMID>
  </reference>
  <reference>
    <citation>Stengel A, Hofmann T, Goebel-Stengel M, Elbelt U, Kobelt P, Klapp BF. Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity--correlation with body mass index. Peptides. 2013 Jan;39:125-30. doi: 10.1016/j.peptides.2012.11.014. Epub 2012 Dec 3.</citation>
    <PMID>23219488</PMID>
  </reference>
  <reference>
    <citation>Huh JY, Panagiotou G, Mougios V, Brinkoetter M, Vamvini MT, Schneider BE, Mantzoros CS. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism. 2012 Dec;61(12):1725-38. doi: 10.1016/j.metabol.2012.09.002. Epub 2012 Sep 25.</citation>
    <PMID>23018146</PMID>
  </reference>
  <reference>
    <citation>Aydin S, Kuloglu T, Aydin S, Eren MN, Celik A, Yilmaz M, Kalayci M, Sahin İ, Gungor O, Gurel A, Ogeturk M, Dabak O. Cardiac, skeletal muscle and serum irisin responses to with or without water exercise in young and old male rats: cardiac muscle produces more irisin than skeletal muscle. Peptides. 2014 Feb;52:68-73. doi: 10.1016/j.peptides.2013.11.024. Epub 2013 Dec 15.</citation>
    <PMID>24345335</PMID>
  </reference>
  <reference>
    <citation>Kuloglu T, Aydin S, Eren MN, Yilmaz M, Sahin I, Kalayci M, Sarman E, Kaya N, Yilmaz OF, Turk A, Aydin Y, Yalcin MH, Uras N, Gurel A, Ilhan S, Gul E, Aydin S. Irisin: a potentially candidate marker for myocardial infarction. Peptides. 2014 May;55:85-91. doi: 10.1016/j.peptides.2014.02.008. Epub 2014 Feb 24.</citation>
    <PMID>24576483</PMID>
  </reference>
  <reference>
    <citation>Aydin S, Aydin S, Kobat MA, Kalayci M, Eren MN, Yilmaz M, Kuloglu T, Gul E, Secen O, Alatas OD, Baydas A. Decreased saliva/serum irisin concentrations in the acute myocardial infarction promising for being a new candidate biomarker for diagnosis of this pathology. Peptides. 2014 Jun;56:141-5. doi: 10.1016/j.peptides.2014.04.002. Epub 2014 Apr 18.</citation>
    <PMID>24747283</PMID>
  </reference>
  <reference>
    <citation>Aronis KN, Moreno M, Polyzos SA, Moreno-Navarrete JM, Ricart W, Delgado E, de la Hera J, Sahin-Efe A, Chamberland JP, Berman R, Spiro A 3rd, Vokonas P, Fernández-Real JM, Mantzoros CS. Circulating irisin levels and coronary heart disease: association with future acute coronary syndrome and major adverse cardiovascular events. Int J Obes (Lond). 2015 Jan;39(1):156-61. doi: 10.1038/ijo.2014.101. Epub 2013 Jun 11.</citation>
    <PMID>24916788</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2015</study_first_submitted>
  <study_first_submitted_qc>July 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2015</study_first_posted>
  <last_update_submitted>January 14, 2017</last_update_submitted>
  <last_update_submitted_qc>January 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>424 General Military Hospital</investigator_affiliation>
    <investigator_full_name>Athanasios D. Anastasilakis</investigator_full_name>
    <investigator_title>Consultant of Endocrinology</investigator_title>
  </responsible_party>
  <keyword>irisin</keyword>
  <keyword>myocardial infarction</keyword>
  <keyword>coronary</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

